Shenzhen Bioeasy Biotechnology Co. Ltd. Market Cap ($337.87 Million)
Market Cap & Net Worth: Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)
Shenzhen Bioeasy Biotechnology Co. Ltd. market cap. Shenzhen Bioeasy Biotechnology Co. Ltd. (SHE:300942) has a market capitalization of $337.87 Million (CN¥2.31 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #13929 globally and #4100 in its home market, demonstrating a -7.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Bioeasy Biotechnology Co. Ltd.'s stock price CN¥5.70 by its total outstanding shares 405077895 (405.08 Million). Also see Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) cash flow conversion for how efficiently the company converts equity into cash flow.
Shenzhen Bioeasy Biotechnology Co. Ltd. Market Cap History (2021–2026)
Shenzhen Bioeasy Biotechnology Co. Ltd. market cap history from 2021 to 2026. Data shows change from $1.69 Billion to $337.87 Million (-27.32% CAGR). Check Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) stock price for real-time trading data and today's change.
Shenzhen Bioeasy Biotechnology Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Bioeasy Biotechnology Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300942 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.12x
Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap is 2.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
40.59x
Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap is 40.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.69 Billion | $597.54 Million | $236.51 Million | 2.83x | 7.14x |
| 2022 | $1.01 Billion | $686.90 Million | $82.97 Million | 1.48x | 12.23x |
| 2023 | $692.93 Million | $254.11 Million | -$184.91 Million | 2.73x | N/A |
| 2024 | $507.99 Million | $224.25 Million | $17.12 Million | 2.27x | 29.68x |
| 2025 | $557.78 Million | $263.23 Million | $13.74 Million | 2.12x | 40.59x |
Competitor Companies of 300942 by Market Capitalization
Companies near Shenzhen Bioeasy Biotechnology Co. Ltd. in the global market cap rankings as of November 4, 2026. Also see Shenzhen Bioeasy Biotechnology Co. Ltd. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Shenzhen Bioeasy Biotechnology Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Shenzhen Bioeasy Biotechnology Co. Ltd. (2021–2026)
Market capitalization of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2021 to today. Between 2021 and today, Shenzhen Bioeasy Biotechnology Co. Ltd.'s market cap moved from $1.69 Billion to $ 337.87 Million, with a yearly change of -27.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥337.87 Million | -39.43% |
| 2025 | CN¥557.78 Million | +9.80% |
| 2024 | CN¥507.99 Million | -26.69% |
| 2023 | CN¥692.93 Million | -31.69% |
| 2022 | CN¥1.01 Billion | -39.94% |
| 2021 | CN¥1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Shenzhen Bioeasy Biotechnology Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $337.87 Million USD |
| MoneyControl | $337.87 Million USD |
| MarketWatch | $337.87 Million USD |
| marketcap.company | $337.87 Million USD |
| Reuters | $337.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more